Key facts
- This page summarizes Mark Simon's Form 4 filing for Cabaletta Bio, Inc. (CABA).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 18 Oct 2022, 21:50.
Mark Simon - 18 Oct 2022 Form 4 Insider Report for Cabaletta Bio, Inc. (CABA)
- Reporting relationship
- Director
- Issuer ticker
- CABA
- Reported as of
- 18 Oct 2022
- Net transaction value
- +$122,121
- SEC form
- 4
- Accepted by SEC
- 18 Oct 2022, 21:50:40 UTC
- Prior SEC filing
- 03 Jun 2022
- Next SEC filing
- 02 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Gerard, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mark Simon filed Form 4 for Cabaletta Bio, Inc. (CABA) on 18 Oct 2022.
Change
- Previous filing in this sequence was filed on 03 Jun 2022.
- Current net transaction value: +$122,121.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CABA
transaction
Common Stock
Purchase
- Transaction value
- $115,286
- Shares
- +118,000
- Change %
- +650%
- Price
- $0.9770*
- Shares after
- 136,144
- Date
- 18 Oct 2022
- Ownership
- Direct
- Footnotes
- F1
CABA
transaction
Common Stock
Purchase
- Transaction value
- $6,835
- Shares
- +7,000
- Change %
- Price
- $0.9764*
- Shares after
- 7,000
- Date
- 18 Oct 2022
- Ownership
- By Spouse
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were purchased at prices ranging from $0.9315 to $0.99, inclusive. The reporting person has provided to the Issuer, and undertakes to provide any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were purchased at prices ranging from $0.9375 to $0.9899, inclusive.